Ratio Therapeutics

About:

Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

Twitter/X: Ratio_Tx

Top Investors: Bristol-Myers Squibb, Cornell University, The Pags Group, Schusterman Family Investments, Duquesne Capital Management

Description:

Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, and more.

Total Funding Amount:

$90M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2021-01-01

Founders:

Jack Hoppin, John Babich

Number of Employees:

1-10

Last Funding Date:

2024-01-17

IPO Status:

Private

Industries: